Literature DB >> 14582780

Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis.

J de Seze1, C Lebrun, T Stojkovic, D Ferriby, M Chatel, P Vermersch.   

Abstract

Devic's neuromyelitis optica (NMO) associates optic neuritis and myelopathy without other neurological signs. Many patients with NMO may be diagnosed as having multiple sclerosis (MS). However, there have been no previous studies comparing these two pathologies and it is still unclear if NMO is a separate entity or a subtype of MS. In the present study, we compared a series of NMO patients with a series of MS patients for whom optic neuritis or myelopathy was the presenting symptom, in order to determine the place of NMO in the spectrum of MS. We retrospectively studied 30 patients diagnosed with NMO and we compared these patients with 50 consecutive MS cases revealed by optic neuritis or acute myelopathy. MS patients were only included if a relapse occurred demonstrating time and space dissemination. We compared the two groups in terms of clinical presentation, laboratory findings (MRI and CSF) and clinical outcome. NMO patients were older and more frequently women than MS patients but the difference was not significant. CSF and MRI data were clearly different: oligoclonal bands (OCB) were found in 23% of NMO cases and 88% of MS (P < 0.001), abnormal brain MRI data were observed in 10% of NMO cases and 66% of MS (P < 0.001) and a large spinal cord lesion was observed in 67% of NMO cases and 7.4% of MS cases (P < 0.001). Clinical outcome was evaluated as more severe in the NMO group (P < 0.001). On the basis of clinical data, all NMO patients but three had dissemination in time and space. When we included MRI parameters, only two of the NMO patients met criteria for MS and one of the MS patients met criteria for NMO. Our study demonstrates that NMO and MS should be considered as two different entities. The respective criteria for NMO and MS were able to distinguish these two pathologies but only when MRI data were applied. This finding could have implications for future therapeutic trials.

Entities:  

Mesh:

Year:  2003        PMID: 14582780     DOI: 10.1191/1352458503ms947oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  22 in total

Review 1.  Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature.

Authors:  Paira Sergio; Benegas Mariana; Ortiz Alberto; Uña Claudia; Rillo Oscar; Mannucci Pablo; Allievi Alberto
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

2.  Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder.

Authors:  Youming long; Yihua He; Yangbo Zheng; Mengyu Chen; Bin Zhang; Cong Gao
Journal:  J Neurol       Date:  2013-12       Impact factor: 4.849

3.  Current and future treatment approaches for neuromyelitis optica.

Authors:  Nicolas Collongues; Jérôme de Seze
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

4.  CSF pleocytosis and expansion of spinal lesions in Japanese multiple sclerosis with special reference to the new diagnostic criteria.

Authors:  Toshiyuki Fukazawa; Seiji Kikuchi; Ryuji Miyagishi; Yusei Miyazaki; Hikoaki Fukaura; Ichiro Yabe; Takeshi Hamada; Kunio Tashiro; Hidenao Sasaki
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

5.  Differential diagnosis of suspected multiple sclerosis: a consensus approach.

Authors:  D H Miller; B G Weinshenker; M Filippi; B L Banwell; J A Cohen; M S Freedman; S L Galetta; M Hutchinson; R T Johnson; L Kappos; J Kira; F D Lublin; H F McFarland; X Montalban; H Panitch; J R Richert; S C Reingold; C H Polman
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

6.  Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices.

Authors:  Amer Awad; Olaf Stüve
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

7.  New insights into neuromyelitis optica.

Authors:  Woojun Kim; Su-Hyun Kim; Ho Jin Kim
Journal:  J Clin Neurol       Date:  2011-09-29       Impact factor: 3.077

8.  Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.

Authors:  Jiwon Oh; Michael Levy
Journal:  Neurol Res Int       Date:  2012-01-29

9.  Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica.

Authors:  Jean-Baptiste Chanson; Melissa Alame; Nicolas Collongues; Frédéric Blanc; Marie Fleury; Gabrielle Rudolf; Jérôme de Seze; Thierry Vincent
Journal:  Clin Dev Immunol       Date:  2013-04-28

10.  Diffuse white matter damage is absent in neuromyelitis optica.

Authors:  F Aboul-Enein; M Krssák; R Höftberger; D Prayer; W Kristoferitsch
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-12       Impact factor: 4.966

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.